UNSPSC 51283939: Mafenide hydrochloride

This classification denotes a carbonic anhydrase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J751V0284. European Medicines Agency schedules Mafenide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02999MIG. Mafenide hydrochloride generally arises in the molecular formula C7H10N2O2S.CLH. The term 'mafenide hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation.

Most nations, for tariff and trade purposes, schedule mafenide hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, MAFENIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mafenide hydrochloride bears US NLM identifiers UMLS ID C2698002 and NCI Concept Code C76107. SMILES: C1CC(CCC1CN)S(=O)(=O)N.CL.

UNSPSC 51283939 Mafenide hydrochloride is a Commodity code that nominally describes a specific topical antimicrobial agent, yet recent state and local procurement activity under this code does not reflect purchases of mafenide itself. Instead, the opportunities tagged to this code show acquisition of other pharmaceutical products — naloxone for overdose reversal and safe drug deactivation systems for community health use — indicating a possible tagging misalignment between the code's nominal scope and the work actually being solicited. State and local issuing bodies accessing this code include health departments and county public health agencies pursuing pharmaceutical supplies and related medical equipment to support community health missions. The procurement vehicles include piggyback cooperative purchasing arrangements (such as the MMCAP Infuse consortium) that allow multiple jurisdictions to leverage negotiated pharmaceutical contracts, as well as traditional competitive invitation-for-bid processes at the county level.

Geographic activity centers on Florida and Illinois based on recent postings. Seminole County, Florida, issued an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through a two-year initial term with one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building in Sanford and electronic bid submission required by July 26, 2023 (note: the source date appears inconsistent). The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline hyclate and ciprofloxacin hydrochloride tablets totaling $2,999,999.11 over a three-year life (12-month initial term plus two renewal options), selected as the lowest responsive and responsible bidder under an IFB process. Given the mismatch between the code's nominal pharmaceutical scope and the actual products appearing in recent solicitations, this code should be validated against the issuing bodies' actual procurement intent before pursuing opportunities tagged to it.